160 related articles for article (PubMed ID: 38272537)
1. Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records.
Doran W; Tunnicliffe L; Muzambi R; Rentsch CT; Bhaskaran K; Smeeth L; Brayne C; Williams DM; Chaturvedi N; Eastwood SV; Dunachie SJ; Mathur R; Warren-Gash C
BMJ Open Diabetes Res Care; 2024 Jan; 12(1):. PubMed ID: 38272537
[TBL] [Abstract][Full Text] [Related]
2. Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus.
Newby D; Linden AB; Fernandes M; Molero Y; Winchester L; Sproviero W; Ghose U; Li QS; Launer LJ; Duijn CMV; Nevado-Holgado AJ
BMJ Open Diabetes Res Care; 2022 Sep; 10(5):. PubMed ID: 36109050
[TBL] [Abstract][Full Text] [Related]
3. No association between metformin initiation and incident dementia in older adults newly diagnosed with diabetes.
Wu CY; Wang C; Saskin R; Shah BR; Kapral MK; Lanctôt KL; Herrmann N; Cogo-Moreira H; MacIntosh BJ; Edwards JD; Swardfager W
J Intern Med; 2024 Jan; 295(1):68-78. PubMed ID: 37747779
[TBL] [Abstract][Full Text] [Related]
4. Metformin use and risk of cancer in patients with type 2 diabetes: a cohort study of primary care records using inverse probability weighting of marginal structural models.
Farmer RE; Ford D; Mathur R; Chaturvedi N; Kaplan R; Smeeth L; Bhaskaran K
Int J Epidemiol; 2019 Apr; 48(2):527-537. PubMed ID: 30753459
[TBL] [Abstract][Full Text] [Related]
5. Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes.
Orkaby AR; Cho K; Cormack J; Gagnon DR; Driver JA
Neurology; 2017 Oct; 89(18):1877-1885. PubMed ID: 28954880
[TBL] [Abstract][Full Text] [Related]
6. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
7. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
8. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
Currie CJ; Poole CD; Gale EA
Diabetologia; 2009 Sep; 52(9):1766-77. PubMed ID: 19572116
[TBL] [Abstract][Full Text] [Related]
9. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
10. Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy.
Salas J; Morley JE; Scherrer JF; Floyd JS; Farr SA; Zubatsky M; Barthold D; Dublin S
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):623-634. PubMed ID: 32363681
[TBL] [Abstract][Full Text] [Related]
11. Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus.
Shi Q; Liu S; Fonseca VA; Thethi TK; Shi L
BMJ Open; 2019 Jul; 9(7):e024954. PubMed ID: 31366635
[TBL] [Abstract][Full Text] [Related]
12. Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.
Lu CH; Yang CY; Li CY; Hsieh CY; Ou HT
Diabetologia; 2018 Mar; 61(3):562-573. PubMed ID: 29138876
[TBL] [Abstract][Full Text] [Related]
13. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
14. Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival.
Currie CJ; Holden SE; Jenkins-Jones S; Morgan CL; Voss B; Rajpathak SN; Alemayehu B; Peters JR; Engel SS
Diabetes Obes Metab; 2018 Apr; 20(4):821-830. PubMed ID: 29119713
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality.
Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
Diabetes Obes Metab; 2014 Oct; 16(10):977-83. PubMed ID: 24762119
[TBL] [Abstract][Full Text] [Related]
16. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.
Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
Diabetes Obes Metab; 2014 Oct; 16(10):957-62. PubMed ID: 24720708
[TBL] [Abstract][Full Text] [Related]
17. Association Between Metformin Initiation and Incident Dementia Among African American and White Veterans Health Administration Patients.
Scherrer JF; Morley JE; Salas J; Floyd JS; Farr SA; Dublin S
Ann Fam Med; 2019 Jul; 17(4):352-362. PubMed ID: 31285213
[TBL] [Abstract][Full Text] [Related]
18. Development of Osteoarthritis in Adults With Type 2 Diabetes Treated With Metformin vs a Sulfonylurea.
Baker MC; Sheth K; Liu Y; Lu D; Lu R; Robinson WH
JAMA Netw Open; 2023 Mar; 6(3):e233646. PubMed ID: 36939700
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Mitochondrial Adenosine Triphosphate-Sensitive Potassium Channel High- vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With Metformin.
Wang MT; Pan HY; Huang YL; Wu LW; Wang PC; Hsu YJ; Lin TC; Lin C; Lai JH; Lee CH
JAMA Netw Open; 2022 Dec; 5(12):e2245854. PubMed ID: 36484988
[TBL] [Abstract][Full Text] [Related]
20. Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population-based cohort study.
Islam N; Reynier P; Douros A; Yu OHY; Filion KB
Diabetes Obes Metab; 2023 Jun; 25(6):1523-1533. PubMed ID: 36722703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
